2',5'-Oligoadenylate Derivatives for RNase L Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective compounds to treat chronic fatigue syndrome (CFS) and infections caused by gamma-retroviruses, as existing treatments are inadequate in addressing the underlying immunological and viral factors.
Innovation Solution
The use of 2',5'-oligoadenylate derivative compounds, specifically those of Formula (I) and its stereochemically isomeric forms, which have increased metabolic stability and the ability to activate RNase L, providing a longer-lasting pharmacological effect and reduced frequency of administration, are proposed for treating CFS and gamma-retrovirus infections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If 2-5A synthetase/RNase L pathway is activated to treat CFS and gamma-retrovirus infections, then antiviral defense is improved, but the frequency of administration must be increased due to short duration of action
Solution Approach 1:
The patent modifies the chemical structure of 2-5A synthetase inhibitors by changing parameters such as the ribose sugar moiety, base composition, and phosphate linkages to create analogs with altered metabolic stability and prolonged duration of action, thereby reducing administration frequency while maintaining antiviral effectiveness
Solution Approach 2:
The invention creates composite molecular structures combining modified sugar moieties, altered base compositions, and specialized phosphate linkages to produce 2-5A synthetase inhibitor analogs that simultaneously achieve enhanced stability and extended pharmacological duration
2Reliability
If existing 2-5A synthetase inhibitors are used, then antiviral activity is achieved, but metabolic stability is insufficient leading to frequent administration
Solution Approach 1:
The patent systematically modifies chemical parameters including the ribose sugar moiety (2'-O-methyl, 2'-fluoro substitutions), base composition (isoguanine, 2-amino-4-hydroxy-6-methylpyrimidine), and phosphate linkage structures to create analogs with enhanced metabolic stability that resist degradation while preserving antiviral activity
3Ease of operation
If administration frequency is reduced for chronic conditions like CFS, then patient compliance is improved, but duration of action must be extended
Solution Approach 1:
The invention modifies molecular parameters to extend the duration of pharmacological effect, creating 2-5A synthetase inhibitor analogs with prolonged activity that enable less frequent dosing schedules, thereby improving patient compliance for chronic conditions like CFS
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The 2',5'-oligoadenylate derivative compounds effectively activate RNase L, offering a more favorable therapeutic ratio and decreased frequency of administration, making them suitable for chronic conditions like CFS and gamma-retrovirus infections, while maintaining antiviral activity.
Implementation Method 1
Biologically active 2-5A binds to and activates a latent endoribonuclease, RNase L, leading to its dimerization and activation. Activated RNase L hydrolyzes single-stranded viral and cellular RNA, thereby inhibiting protein synthesis.
Implementation Method 2
Activated RNase L hydrolyzes single-stranded viral and cellular RNA, thereby inhibiting protein synthesis.
Data Source
AI summary
The invention relates to the therapeutic uses of 2',5'-oligoadenylate derivative compounds, more particularly for the treatment of chronic fatigue syndrome (CFS) and in the treatment of infection by a gamma-retrovirus.